Sun Pharma: Sun Pharma’s focus on specialty drugs pays off
Even as the raw material cost climbed down from 25% of revenues a year ago to 23% in the September quarter, the other expenses increased from 28% of revenues to …
pharma
stocks to buy: From now till 2024 elections a very good time to buy stocks; look at these 3 sectors: Abhishek Basumallick
Abhishek Basumallick, Founder & Chief Equity Advisor, Intelsense Capital, says “right now is a very good time to buy for probably the next two to three years. Right now means …
Concord Biotech: Concord Biotech’s niche strengths seen buoying earnings: Analysts
Mumbai: Concord Biotech’s strong foothold in the niche segment of manufacturing active pharmaceutical ingredients through fermentation along with its capacity expansion and planned launches are seen underpinning strong earnings growth …